5 years ago

Genetic predictors of response to systemic therapy in esophagogastric cancer.

Barry S Taylor, Valerie W Rusch, Jamie C Riches, Marc Ladanyi, Ahmet Zehir, Sumit Middha, Daniela Molena, Manjit Bains, Daniel G Coit, Efsevia Vakiani, Philip Jonsson, Nikolaus Schultz, Jinru Shia, David P Kelsen, Walid K Chatila, Laura Tang, Mark E Robson, David M Hyman, Hans Gerdes, Vivian E Strong, Yaelle Tuvy, Zachary J Heins, Geoffrey Y Ku, David H Ilson, Jianjiong Gao, David B Solit, Michael F Berger, David R Jones, Benjamin E Gross, Liying Zhang, Neal Rosen, Maurizio Scaltriti, Jaclyn F Hechtman, Francisco Sanchez-Vega, Nancy Bouvier, Marinela Capanu, Zsofia K Stadler, Yelena Y Janjigian, Mark Schattner, Ritika Kundra
The incidence of esophagogastric cancer is rapidly rising but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance, we implemented prospective tumor sequencing of metastatic esophagogastric cancer patients. There was no association between HRD defects and response to platinum-based chemotherapy. Patients with MSI-H tumors were intrinsically resistant to chemotherapy but more likely to achieve durable responses to immunotherapy. The single EBV+ patient achieved a durable, complete response to immunotherapy. The level of ERBB2 amplification as determined by sequencing was predictive of trastuzumab benefit. Selection for a tumor subclone lacking ERBB2 amplification, deletion of ERBB2 exon 16, and co-mutations in the receptor tyrosine kinase, RAS, PI3K pathways were associated with intrinsic and/or acquired trastuzumab resistance. Prospective genomic profiling can identify patients most likely to derive durable benefit to immunotherapy and trastuzumab, and guide strategies to overcome drug resistance.

Publisher URL: http://doi.org/10.1158/2159-8290.CD-17-0787

DOI: 10.1158/2159-8290.CD-17-0787

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.